UBE2I

Across TCGA pan-cancer cohorts, UBE2I RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated UBE2I data layer compared with 2 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher UBE2I RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBE2I expression acts as an unfavorable survival marker, although some lineages such as COAD and UVM show a favorable association.

LIHC, PAAD, and COAD are the cancer types where UBE2I RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.469	0.610	.002	48	view →
PAAD	OS	Median	All	0.229	0.663	<.001	47	view →
COAD	OS	Median	III,IV	0.838	0.720	.005	46	view →
LGG	DFS	Quartile	All	0.640	0.816	<.001	35	view →
UVM	DFS	Median	III,IV	0.779	0.289	<.001	24	view →
THCA	OS	Quartile	All	1.000	0.766	.010	18	view →
KIRP	DFS	Quartile	II,III,IV	0.125	1.000	.003	16	view →
KICH	OS	Tertile	II,III,IV	1.000	0.400	.022	14	view →
KIRC	DFS	Tertile	II,III,IV	0.685	0.840	.013	13	view →
SCLC	DFS	Tertile	II,III,IV	0.524	0.200	.010	12	view →
OV	OS	Median	IV	0.854	0.645	.024	12	view →
THYM	OS	Tertile	All	1.000	0.770	.010	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

UBE2I–LIHC (DFS)

Open the LIHC breakdown →